Top Baltimore, MD Biotech Companies (24)
DELFI uses artificial intelligence and whole genome sequencing to sensitively detect unique patterns of DNA fragmentation in the blood of patients with cancer.
Breethe is a medical device company that develops a compact artificial lung for patients with acute and chronic lung problems.
CoapTech is an early-stage medical device company aiming to improve medical care delivery for patients young and old around the world.
Minnowtech is an aquaculture technology company,
Capsulomics specializes in the fields of diagnostics, medical device, medicine, early detection, and medtech.
Johns Hopkins Medicine is a governing structure for the University’s School of Medicine and the health system, coordinating their research, teaching, patient care, and related enterprises. The Johns Hopkins Hospital opened in 1889, followed four years later by the university’s School of Medicine, revolutionizing medical practice, teaching, and research in the United States. The hospital is now part of the Johns Hopkins Health System, which includes two other acute-care hospitals and additional integrated health-care delivery components, with a network of primary and specialty care practices throughout Maryland, outpatient care, long-term care, and home care. The Johns Hopkins University opened in 1876 as America’s first research university, founded for the express purpose of expanding knowledge and putting that knowledge to work for the good of humanity. Two Interconnected Institutions: Over the years, the University and Hospital have grown, and—sometimes jointly, sometimes separately—they have created affiliated organizations. The Johns Hopkins Institutions is a collective name for the University and the Johns Hopkins Health System. The Johns Hopkins University includes nine academic and research divisions, and numerous centers, institutes, and affiliated entities. Johns Hopkins Medicine is a governing structure for the University’s School of Medicine and the health system, coordinating their research, teaching, patient care, and related enterprises.
Lab-quality, Clinically Actionable Results in Minutes Anywhere! Novel Dx detects the genetic material of pathogens using Nucleic Acid Amplification techniques. These are the same methods that are utilized in large reference laboratories Novel Dx delivers lab-quality results in under 30 minutes so patients can be tested and treated in the same visit
Fzata, Inc. is a pre-clinical stage biopharmaceutical company based in Halethorpe, MD within the vibrant BioHealth Capital Region. Fzata’s vision is to reduce health inequities by expanding patient access to therapeutic biologics. This is made possible with our proprietary first-in-class oral Bioengineered Probiotic Yeast Medicines (BioPYM™) platform. BioPYM enables orally administered yeast micro-factories to make biologic therapeutics “on-site” in the gut for treatment of GI disorders like infectious diseases, inflammation, metabolic diseases, (e.g., diabetes), colon cancer, and more. Our oral biologic drug candidates are intended to help patients that inject biologic medicine by 1) improving patient accessibility to biologics with affordable, non-refrigerated, convenient oral capsules, 2) improving patient compliance with no needles and no need for health-care administration and 3) improving patient outcomes given the expected high safety profile for chronic use.
Glyscend develops a revolutionary approach to treating type 2 diabetes.
KaloCyte, Inc., a pre-clinical stage healthcare biotech startup company, located at the University of Maryland, Baltimore (UMB) as an Affiliate of the UM BioPark. KaloCyte’s offices and labs are sited within the UM School of Medicine’s Center for Blood Oxygen Transport and Hemostasis (CBOTH) directed by Allan Doctor, MD (KaloCyte Co-Founder and CSO). KaloCyte was founded in 2016 by a distinguished team of Washington University in St. Louis researchers in physiology, bioengineering, and trauma care, with support from the BioGenerator Fundamentals program. KaloCyte has demonstrated proof of concept for ErythroMer, a dried, bio-inspired artificial red blood cell envisioned for use when stored red blood cells are unavailable, undesirable or in short supply. KaloCyte is supported by $7.5M in federal awards and $2.5M investor funding. ErythroMer is a first-in-class, bio-inspired nanoparticle-encapsulated human hemoglobin, which mimics the vital oxygen-carrying functionality of RBCs and can be freeze-dried for long-term storage. Erythromer’s synthetic outer membrane, donut-shape and surface area allow for physiologically realistic gas exchange. The synthetic polymer shell is “immune-silent”, inert and carries no blood antigens, eliminating the need to type and cross-match as with stored blood. ErythroMer can be freeze-dried or “lyophilized”, for a much longer shelf life than stored blood. It is covered by issued U.S. patents that specify composition of matter, method of preparation, and use as an oxygen carrier.
VakSea is a biotechnology company that makes immune-boosting protein to immunize and protect shrimp from the disease.
Revolve Biotechnologies is a biotechnology platform.
Emergent BioSolutions is a global life sciences company whose mission is to protect and enhance life. Through our specialty products and contract development and manufacturing services, we are dedicated to providing solutions that address public health threats. Through social responsibility, we aim to build healthier and safer communities. We aspire to deliver peace of mind to our patients and customers so they can focus on what’s most important in their lives. In working together, we envision protecting or enhancing 1 billion lives by 2030. For more information visit www.emergentbiosolutions.com. Follow us on Twitter @emergentbiosolu and Instagram @life_at_emergent.
ReGelTec is a medical device company.
LifeSprout is developing the next-generation of synthetic soft tissue substitutes for aesthetic and reconstructive medicine.
Brinkbit is a fast, extensible, and scalable BaaS platform for game services, content management, live ops, and more!
We are a team of dedicated scientists striving to advance treatments in multiple indications in our cell therapy platform. Our mission is to utilize the power of genetics to deliver life-transformative cell therapies by unlocking the potential of engineered cellular medicine.
Avidea Technologies is a developer of polymer-based drugs intended to provide vaccines for cancer treatment and infectious diseases.
Y-Trap Inc. is a biotechnology company.
DITCH THE “CRUTCH” Working alongside Physical Therapists we help patients improve walking function with the goal of discarding their assistive devices. The Problem: Approximately 30% of the 800,000 new strokes in the United States result in foot drop. Globally, there are 17 million new strokes per year. Nearly half are left with persistent mobility deficits even after completion of all conventional therapy, which invariably involve ankle weakness; a crucial joint for walking and balance. The existing 125,000 rehabilitation centers cannot effectively treat foot drop with current methods and are left to prescribing rigid archaic braces to imobilize the ankle. Current Solutions: "Crutches" - Currently the treatment for foot drop is to immobilize and brace the ankle. This technology has not seen much change since King Tut used his crutches. A New Option: We are developing a low cost and portable ankle robot that will treat foot drop in a way not yet accomplished before. Real Results: 85% of participants in a small randomized study self discarded their ankle foot orthotics or reduced dependance of their assistive devices. Forrester LW, Roy A, Hafer-Macko C, Krebs HI, Macko RF. Task-specific ankle robotics gait training after stroke: a randomized pilot study. Journal of NeuroEngineering and Rehabilitation. 2016;13:51.
Work Your Passion. Live Your Purpose.
